Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.

Weiss A, Adler F, Buhles A, Stamm C, Fairhurst RA, Kiffe M, Sterker D, Centeleghe M, Wartmann M, Kinyamu-Akunda J, Schadt HS, Couttet P, Wolf A, Wang Y, Barzaghi-Rinaudo P, Murakami M, Kauffmann A, Knoepfel T, Buschmann N, Leblanc C, Mah R, Furet P, Blank J, Hofmann F, Sellers WR, Graus Porta D.

Mol Cancer Ther. 2019 Dec;18(12):2194-2206. doi: 10.1158/1535-7163.MCT-18-1291. Epub 2019 Aug 13.

PMID:
31409633
2.

AAV2-mediated in vivo immune gene therapy of solid tumours.

Collins SA, Buhles A, Scallan MF, Harrison PT, O'Hanlon DM, O'Sullivan GC, Tangney M.

Genet Vaccines Ther. 2010 Dec 20;8:8. doi: 10.1186/1479-0556-8-8.

3.

Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours.

Buhles A, Collins SA, van Pijkeren JP, Rajendran S, Miles M, O'Sullivan GC, O'Hanlon DM, Tangney M.

Genet Vaccines Ther. 2009 Mar 9;7:5. doi: 10.1186/1479-0556-7-5.

Supplemental Content

Loading ...
Support Center